{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-002832","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.645145+00:00","generated_at":"2026-06-11T14:39:47.291696+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entera Bio reports H1 net loss $4.5M, cash $9.1M; updates on EB613 and EB612 trials","bullets":["H1 2023 net loss $4.5M ($0.16/share) vs $7.0M ($0.24) in H1 2022.","Cash and equivalents $9.1M expected to fund operations into Q3 2024.","R&D expenses $2.1M (down 32% YoY); G&A $2.4M (down 41% YoY).","EB613 Phase 3 initiation depends on FDA review of FNIH-ASBMR SABRE BQP qualification.","Phase 1B study of next-gen EB612 platform (45 subjects, 3 cohorts) started May 2023; H2 2023 data readout expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-002832","json":"https://secwatch.observer/filing/0001178913-23-002832.json","markdown":"https://secwatch.observer/filing/0001178913-23-002832.md","text":"https://secwatch.observer/filing/0001178913-23-002832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/0001178913-23-002832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/zk2330154.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:39:47.291696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c25cfa6e85ba5bf76b892b6176cdbbd0474aeeb","claim":"Entera Bio Ltd. reported the six months ended June 30, 2023 results: net income Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, EPS $0.16 per ordinary share (basic and diluted).","evidence_excerpt":"Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, as compared to $7.0 million, or $0.24 per ordinary share (basic and diluted), for the six months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/0001178913-23-002832-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Net income","value":"Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023"},{"label":"EPS","value":"$0.16 per ordinary share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}